99 results about "Pancreatic duct" patented technology

An expandable biodegradable polymeric stent is fabricated with biodegradable polymer fibers (Poly-L-lactic acid, PLLA) in a coil shape that is constructed with both central and external or internal peripheral lobes. It is delivered and expanded using a conventional angioplasty balloon system. The disclosed stent can serve as a temporary scaffold for coronary vessels after PTCA or for peripheral endovascular stenting, or it can provide mechanical palliation for strictures of ductile organs (trachea, esophagus, bile and pancreatic ducts, ureter etc.). The disclosed stent also serves as a unique device for specific local drug delivery. Therapeutic agents (chemical compounds, protein enzyme and DNA sequences) and cells can be loaded into the stent and gradually released to target tissues. Local radiation therapy can also be delivered by a specially adapted stent.

Advanced Bioreactor Cell Culture Technology presents a method of cell culturing and bioprocessing incorporating molecular biology techniques, advanced process control methodology, and a process control interface applied to a two liquid phase cell culture bioreactors to proliferate, grow, and expand non-differentiated precursor cells, embryonic stem (ES) cells, endocrine progenitor cells, pancreatic progenitor cells, pancreatic stem cells, pancreatic duct epithelial cells, nestin-positive islet-derived progenitor cells (NIPs), or pluripotent non-embryonic stem (PNES) cells in the bioreactor, and influence, stimulate, and induce the non-differentiated precursors and progenitors into fully differentiated beta cell phenotypes; including microprocessor control of cell culture process variables and data acquisition during bioprocessing. The invention may be applied to precursors and progenitor cells either transgenic or non-transgenic derived from animals and mammals.

Methods of treating ovarian cancer, endometrium cancer, cervical cancer, pancreatic cancer, bladder cancer, eve cancer, central nervous system cancer, thyroid cancer and lung cancer are disclosed. Specifically disclosed are methods of treating ovarian adenocarcinoma that has migrated into the abdominal cavity, a transitional cell carcinoma of the bladder, an epithelioid carcinoma in a pancreatic duct, an adenocarcinoma in a pancreatic duct, an adenocarcinoma in the cervical epithelium. The methods comprise administering to a patient a therapeutically effective amount of a compound of formula (Ia)wherein R1, R2, R3, R4, and R5 are described herein, wherein at least two of the five R1, R2, R3, R4, and R5 substituents are always hydrogen, at least one of the five substituents is always nitro, and at least one substituent positioned adjacent to a nitro is always iodo, and pharmaceutically acceptable salts thereof.

The invention belongs to the field of medical devices, and relates to a medical device for recovering targeted components of a cavity content. The device recovers the targeted components of the human body cavity content in vitro. The device can be used for greatly preparing a fecal bacterium solution with parasitic ova removed to support a preparation procedure of standardized fecal bacterium transplantation, used for greatly collecting the parasitic ova in a fecal suspension to increase a positive detection rate of the parasitic ova, used for collecting deslagged secretions in intestine and stomach cavities by an endoscope to meet requirements of checking and diagnosis, used for collecting lavage liquid in a trachea and removing slag by the endoscope to meet requirements of a hormone test and cytological examination, and used for collecting liquid of biliary and pancreatic ducts and a urogenital canal to meet requirements of the checking and the cytological examination. The method solves the practical problems of clinical applications, and has important innovation and an application value.

A method and apparatus for treating a patient's health condition by diverting pancreatic exocrine secretions include a flow diverter of material compatible with chronic residence within a small intestine of the patient. The flow diverter has a cover end and a discharge end. The flow diverter is sized to be placed within the small intestine with the discharge end placed distally from said cover end and with said flow diverter further sized so permit passage of chyme through the small intestine and past the flow diverter. The cover end is sized to cover a discharge papilla of the pancreatic duct. The diverter is adapted to divert at least a portion of pancreatic exocrine secretion from the papilla to the distal discharge end.

The invention discloses a guide wire navigation method for endoscopic biliary stent implantation for portal stenosis and a guide wire navigation system thereof. The method comprises the following steps: S1, receiving an input magnetic resonance pancreatic duct imaging image of a patient with portal stenosis; S2, performing image segmentation on the magnetic resonance pancreatic duct imaging imageof the patient with the hilar biliary stenosis based on an image segmentation method of deep learning, and predicting a navigation line from the tail end of the biliary duct to a hilar stenosis part;S3, receiving a real-time perspective image in an endoscopic retrograde cholangiopancreatography; S4, registering the two images according to the key points of the biliary duct on a magnetic resonance cholangiopancreatography image and the key points of the guide wire on the perspective image in the endoscopic retrograde cholangiopancreatography; and S5, displaying a registered composite image, and when the predicted navigation line in the composite image is not matched with the inserted guide wire, changing the position of the guide wire until the predicted navigation line is matched with the inserted guide wire. The method and the system can guide a doctor to perform biliary duct intubation, help the doctor to judge whether biliary duct intubation is correct or not, and reduce the use amount of a contrast media during an operation so as to reduce postoperative complications.

An expandable biodegradable polymeric stent is fabricated with biodegradable polymer fibers (Poly-L-lactic acid, PLLA) in a coil shape that is constructed with both central and external or internal peripheral lobes. It is delivered and expanded using a conventional angioplasty balloon system. The disclosed stent can serve as a temporary scaffold for coronary vessels after PTCA or for peripheral endovascular stenting, or it can provide mechanical palliation for strictures of ductile organs (trachea, esophagus, bile and pancreatic ducts, ureter etc.). The disclosed stent also serves as a unique device for specific local drug delivery. Therapeutic agents (chemical compounds, protein enzyme and DNA sequences) and cells can be loaded into the stent and gradually released to target tissues. Local radiation therapy can also be delivered by a specially adapted stent.

A balloon catheter (400) may include a distal anchoring balloon (404) and a proximal hub (410) that is removable from the catheter body. The catheter body may include a valve structure (420) providing for maintaining the balloon in an inflated state during and after removal of the proximal hub. The valve preferably is constructed such that removal of the hub provides a low-profile proximal catheter end that will allow that proximal catheter end to pass through an endoscopic surgical device such as, for example, through an accessory channel of a standard duodenoscope and / or an ultra- slim endoscope / cholangioscope, facilitating a scope- exchange for use during, for example, a cholangioscopy or pancreatoscopy procedure. A method useful for scope exchange and / or introducing another elongate surgical device may utilize a balloon catheter with a distal anchoring balloon and a proximal hub that is removable from the catheter body.

The invention belongs to the field of medical devices, and relates to a medical device for recovering targeted components of a cavity content. The device recovers the targeted components of the human body cavity content in vitro. The device can be used for greatly preparing a fecal bacterium solution with parasitic ova removed to support a preparation procedure of standardized fecal bacterium transplantation, used for greatly collecting the parasitic ova in a fecal suspension to increase a positive detection rate of the parasitic ova, used for collecting deslagged secretions in intestine and stomach cavities by an endoscope to meet requirements of checking and diagnosis, used for collecting lavage liquid in a trachea and removing slag by the endoscope to meet requirements of a hormone test and cytological examination, and used for collecting liquid of biliary and pancreatic ducts and a urogenital canal to meet requirements of the checking and the cytological examination. The method solves the practical problems of clinical applications, and has important innovation and an application value.

The present invention relates to a multipotent stem cell, multipotent cell populations, and an enriched multipotent cell population, each found in fetal, neonatal, pediatric, and adult biliary tree tissue and up to 72 hours post mortem (although preferentially, within 10 hours post mortem) and capable of maturing into multiple endodermal tissues that include liver, biliary and pancreatic tissues. The multipotent stem / progenitor cell and cell populations are found in peribiliary glands, and progenitors descending from them are present throughout the biliary tree including in the gallbladder. High numbers of the peribiliary glands are found in the branching locations of the biliary tree such as hilum, common hepatic duct, cystic duct, common duct, common hepato-pancreatic duct and gallbladder. Related multipotent cells, multipotent cell populations and their descendent progenitors are found throughout the biliary tree including in the gall bladder, which does not have peribiliary glands. Compositions comprising same, methods of identifying and isolating same, maintaining same in culture, expanding same in culture and differentiating or lineage restricting the same in vitro or in vivo to hepatic, biliary or pancreatic fates (e.g., as hepatocytes, cholangiocytes, and / or pancreatic islet cells) are also provided. Methods of using the multipotent cells and / or multipotent cell populations are also provided.

The invention provides a pancreaticojejunostomy support barb tube, belongs to the field of medical instruments, and solves the problem of high suture difficulty in the present pancreaticojejunostomy.The pancreaticojejunostomy support barb tube comprises a support tube which comprises a pancreatic duct and an intestinal duct. The pancreatic duct is used for being inserted into the pancreatic end.The intestinal duct is used for being inserted into the jejunum end. The surfaces of the pancreatic duct and the intestinal duct are provided with barbs. A mark ring is arranged at the junction of thepancreatic duct and the intestinal duct for marking the length of the pancreatic duct inserted into the pancreaticojejunum and the length of the intestinal duct inserted into the jejunum. The pancreaticojejunostomy support barb tube has the advantages of reducing the difficulty of the pancreaticojejunostomy.

The invention provides an amplification method of pancreatic cells. The amplification method comprises the following steps: sequentially carrying out digestion treatment, resuspension treatment, discontinuous density gradient centrifugation treatment and amplification treatment on pancreatic tissues. According to the amplification method disclosed by the invention, pancreatic ducts of mammals are used as sources of pancreatic precursor-like cells, and islet cells and acinar cells in obtained cell clusters are removed after the discontinuous density gradient centrifugal treatment, thus being good for improving the yield of pancreatic precursor-like cells, and avoiding ethical limitations and possible carcinogenic risk caused by the use of embryonic stem cells; and an amplification culture medium used in the invention comprises a reprogramming substance consisting of a plurality of small molecule compounds, so as to avoid the risks of nonspecificity, off-target deletion, etc., which are easily caused by changing gene sequences by using a gene editing method. The invention also provides a differentiation method and application of the pancreatic precursor-like cells obtained by the amplification method.